These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 23127933)

  • 1. [Molecular entities of the breast cancer: the difference is in the origin].
    Charafe-Jauffret E; Ginestier C
    Ann Pathol; 2012 Nov; 32(5 Suppl):S35-6. PubMed ID: 23127933
    [No Abstract]   [Full Text] [Related]  

  • 2. Breast cancer intra-tumor heterogeneity.
    Martelotto LG; Ng CK; Piscuoglio S; Weigelt B; Reis-Filho JS
    Breast Cancer Res; 2014 May; 16(3):210. PubMed ID: 25928070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is ALDH1 a good method for definition of breast cancer stem cells?
    Neumeister V; Rimm D
    Breast Cancer Res Treat; 2010 Aug; 123(1):109-11. PubMed ID: 19946740
    [No Abstract]   [Full Text] [Related]  

  • 4. Breast cancer stem cells: initiating a new sort of thinking.
    Herschkowitz JI
    Dis Model Mech; 2010; 3(5-6):257-8. PubMed ID: 20427552
    [No Abstract]   [Full Text] [Related]  

  • 5. Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer.
    Rennstam K; McMichael N; Berglund P; Honeth G; Hegardt C; Rydén L; Luts L; Bendahl PO; Hedenfalk I
    Breast Cancer Res Treat; 2010 Jul; 122(2):315-24. PubMed ID: 19795205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insights into the cell of origin in breast cancer and breast cancer stem cells.
    Lindeman GJ; Visvader JE
    Asia Pac J Clin Oncol; 2010 Jun; 6(2):89-97. PubMed ID: 20565420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype.
    Ricardo S; Vieira AF; Gerhard R; Leitão D; Pinto R; Cameselle-Teijeiro JF; Milanezi F; Schmitt F; Paredes J
    J Clin Pathol; 2011 Nov; 64(11):937-46. PubMed ID: 21680574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast Tumor Heterogeneity: Source of Fitness, Hurdle for Therapy.
    Koren S; Bentires-Alj M
    Mol Cell; 2015 Nov; 60(4):537-46. PubMed ID: 26590713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome.
    Idowu MO; Kmieciak M; Dumur C; Burton RS; Grimes MM; Powers CN; Manjili MH
    Hum Pathol; 2012 Mar; 43(3):364-73. PubMed ID: 21835433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarkers in breast cancer.
    Vivanco Md
    Methods Mol Biol; 2010; 593():137-56. PubMed ID: 19957148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological progression of breast cancer and clinical implications.
    Vici P; Sergi D; Pizzuti L; Vincenzoni C; Baiocco E; Mancini E; Lopez M; Vizza E; Lauro LD
    Clin Ter; 2011; 162(4):297-9. PubMed ID: 21912815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer stem cells markers CD44, CD24 and ALDH1 in breast cancer special histological types.
    de Beça FF; Caetano P; Gerhard R; Alvarenga CA; Gomes M; Paredes J; Schmitt F
    J Clin Pathol; 2013 Mar; 66(3):187-91. PubMed ID: 23112116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathologic correlation of cancer stem cell markers CD44, CD24, VEGF and HIF-1α in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.
    Wang Z; Shi Q; Wang Z; Gu Y; Shen Y; Sun M; Deng M; Zhang H; Fang J; Zhang S; Xie F
    Pathol Res Pract; 2011 Aug; 207(8):505-13. PubMed ID: 21802218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Breast cancer stem cells].
    Yasuda K; Hirohashi Y; Torigoe T
    Nihon Rinsho; 2012 Sep; 70 Suppl 7():76-83. PubMed ID: 23350369
    [No Abstract]   [Full Text] [Related]  

  • 15. Heterogeneity of breast cancer: etiology and clinical relevance.
    Almendro V; Fuster G
    Clin Transl Oncol; 2011 Nov; 13(11):767-73. PubMed ID: 22082639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exosomes from breast cancer cells can convert adipose tissue-derived mesenchymal stem cells into myofibroblast-like cells.
    Cho JA; Park H; Lim EH; Lee KW
    Int J Oncol; 2012 Jan; 40(1):130-8. PubMed ID: 21904773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of Notch signaling reduces the stem-like population of breast cancer cells and prevents mammosphere formation.
    Grudzien P; Lo S; Albain KS; Robinson P; Rajan P; Strack PR; Golde TE; Miele L; Foreman KE
    Anticancer Res; 2010 Oct; 30(10):3853-67. PubMed ID: 21036696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective reduction of estrogen receptor (ER) positive breast cancer occurrence by estrogen receptor modulators supports etiological distinction between ER positive and ER negative breast cancers.
    Kurbel S
    Med Hypotheses; 2005; 64(6):1182-7. PubMed ID: 15823713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Tumor stem cells in breast cancer].
    Ivanov AA; Popova OP; Kuznetsova AV; Danilova TI
    Arkh Patol; 2015; 77(5):64-67. PubMed ID: 27077156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast Cancer Intra-Tumor Heterogeneity: One Tumor, Different Entities.
    Esparza-López J; Escobar-Arriaga E; Soto-Germes S; Ibarra-Sánchez MJ
    Rev Invest Clin; 2017; 69(2):66-76. PubMed ID: 28453505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.